BioSpace News Archive

Revance Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, at a price to the public of $25.00 per share.

Stealth BioTherapeutics Corp (NASDAQ: MITO), today announced that the company is participating in upcoming events to discuss challenges and opportunities in ultra-rare disease drug development.

Medexus Pharmaceuticals held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus’s management information circular dated August 5, 2022 as directors through the next annual meeting.

Global Blood Therapeutics, Inc. announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease treatment, research and education.

ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVOTM Sleep and Snore Device is now reimbursable by Germany’s public health insurance system.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.

Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common stock.

J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02' at the ESMO 2022, that showed high potency of JIN-A02 against both cis and trans isomers of C797S mutation.

NuGen Medical Devices Inc. is pleased to announce that it has made an application to the TSX Venture Exchange to extend the expiry date and reduce the exercise price of an aggregate of 7,500,000 outstanding common share purchase warrants of the Company which were originally issued in connection with the private placement of subscription receipts of the Company on December 30, 2020.

Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, announced that it entered into a Pre-Paid Advance Agreement with YA II PN, LTD, an affiliate of Yorkville Advisors Global, LP.